Osterweis Capital Management Inc. Makes New Investment in Glaukos Corporation $GKOS

Key Points

• Osterweis Capital Management Inc. has acquired a new position in Glaukos Corporation, purchasing 59,133 shares valued at approximately $5.82 million.
• Other hedge funds also increased their stakes significantly in Glaukos, with some like Whipplewood Advisors LLC growing by nearly 3,957.1% during the first quarter.
• Analysts have mixed ratings for Glaukos, with target prices ranging from $92.00 to $134.00, reflecting a consensus average target price of $124.83.

Osterweis Capital Management Inc. bought a new position in shares of Glaukos Corporation (NYSE:GKOS - Free Report) in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 59,133 shares of the medical instruments supplier's stock, valued at approximately $5,820,000. Osterweis Capital Management Inc. owned about 0.10% of Glaukos as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds also recently modified their holdings of GKOS. Bessemer Group Inc. increased its position in Glaukos by 133.9% during the first quarter. Bessemer Group Inc. now owns 276 shares of the medical instruments supplier's stock worth $27,000 after acquiring an additional 158 shares during the period. Whipplewood Advisors LLC increased its position in Glaukos by 3,957.1% during the first quarter. Whipplewood Advisors LLC now owns 284 shares of the medical instruments supplier's stock worth $28,000 after acquiring an additional 277 shares during the period. First Horizon Advisors Inc. increased its position in Glaukos by 72.9% during the first quarter. First Horizon Advisors Inc. now owns 377 shares of the medical instruments supplier's stock worth $37,000 after acquiring an additional 159 shares during the period. Versant Capital Management Inc increased its position in Glaukos by 583.9% during the first quarter. Versant Capital Management Inc now owns 383 shares of the medical instruments supplier's stock worth $38,000 after acquiring an additional 327 shares during the period. Finally, Bayforest Capital Ltd bought a new position in Glaukos during the first quarter worth about $141,000. Institutional investors and hedge funds own 99.04% of the company's stock.

Glaukos Trading Up 0.0%

Shares of Glaukos stock opened at $87.53 on Friday. The firm has a market capitalization of $5.02 billion, a PE ratio of -53.05 and a beta of 0.77. The company has a current ratio of 5.51, a quick ratio of 4.69 and a debt-to-equity ratio of 0.09. The firm's 50 day moving average is $93.90 and its 200 day moving average is $96.08. Glaukos Corporation has a 1 year low of $77.10 and a 1 year high of $163.71.

Glaukos (NYSE:GKOS - Get Free Report) last posted its earnings results on Wednesday, July 30th. The medical instruments supplier reported ($0.24) earnings per share for the quarter, topping analysts' consensus estimates of ($0.26) by $0.02. Glaukos had a negative net margin of 21.43% and a negative return on equity of 8.59%. The firm had revenue of $124.12 million for the quarter, compared to analyst estimates of $115.49 million. During the same period in the previous year, the firm posted ($0.52) EPS. The company's revenue for the quarter was up 29.7% compared to the same quarter last year. Glaukos has set its FY 2025 guidance at EPS. Equities research analysts forecast that Glaukos Corporation will post -1.08 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts recently commented on the stock. William Blair raised shares of Glaukos to a "strong-buy" rating in a research report on Thursday, July 31st. Zacks Research lowered shares of Glaukos from a "strong-buy" rating to a "hold" rating in a report on Friday, August 15th. UBS Group raised their target price on shares of Glaukos from $125.00 to $134.00 and gave the company a "buy" rating in a report on Thursday, July 31st. Wells Fargo & Company raised their target price on shares of Glaukos from $86.00 to $92.00 and gave the company an "equal weight" rating in a report on Thursday, July 31st. Finally, BTIG Research reissued a "buy" rating and issued a $118.00 target price on shares of Glaukos in a report on Wednesday. One analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $124.83.

Glaukos Company Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.